SCHEMBL2740957

SCHEMBL2740957

CC(C)C/C=N/Nc1ccc([N+](=O)[O-])cc1S(=O)(=O)Nc1ccccc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 10/20 0.50
▸ KMT2A Q03164 10/20 0.50
▸ HTT P42858 5/20 0.50
▸ SMN1; SMN2 Q16637 4/20 0.50
▸ RAB9A P51151 3/20 0.50
▸ PSMD14 O00487 2/20 0.50
▸ NPC1 O15118 2/20 0.50
▸ CRHBP P24387 2/20 0.47
▸ CRHR2 Q13324 2/20 0.47
▸ MAPT P10636 8/20 0.47
▸ GAA P10253 4/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ TNNI3 P19429 1/20 0.47
▸ TNNT2 P45379 1/20 0.47
▸ TNNC1 P63316 1/20 0.47
▸ GLA P06280 1/20 0.47
▸ TLR9 Q9NR96 1/20 0.47
▸ ALPL P05186 1/20 0.47
▸ ALPI P09923 1/20 0.47
▸ ALPG P10696 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2740989 0.89 MEN1 (0.52) MEN1KMT2AHTTSMN1; SMN2RAB9A
SCHEMBL14160336 0.85 MEN1 (0.49) MEN1KMT2AHTTSMN1; SMN2RAB9A
SCHEMBL2740948 0.81 L3MBTL1 (0.55) MEN1KMT2AHTTSMN1; SMN2RAB9A
SCHEMBL2741006 0.80 MEN1 (0.55) MEN1KMT2AHTTSMN1; SMN2RAB9A
SCHEMBL2741012 0.80 CRHBP (0.53) MEN1KMT2AHTTSMN1; SMN2RAB9A
SCHEMBL2740976 0.79 PSMD14 (0.53) MEN1KMT2AHTTSMN1; SMN2RAB9A
SCHEMBL2740990 0.79 L3MBTL1 (0.57) MEN1KMT2AHTTSMN1; SMN2RAB9A
SCHEMBL2740986 0.79 MEN1 (0.56) MEN1KMT2AHTTSMN1; SMN2RAB9A
SCHEMBL2740974 0.79 MEN1 (0.52) MEN1KMT2AHTTSMN1; SMN2RAB9A
SCHEMBL2740987 0.78 MEN1 (0.55) MEN1KMT2AHTTSMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088772-B2 Sulfonamides and their use as a medicament THE GENETICS COMPANY, INC. (CH) 2012-01-03 — — US disclosed
US-8088772-B2 Sulfonamides and their use as a medicament THE GENETICS COMPANY, INC. (CH) 2012-01-03 — — US disclosed
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT THE GENETICS COMPANY, INC. (CH) 2010-09-30 — — US disclosed
EP-1932830-A1 Sulfonamides and their use as a medicament The Genetics Company, Inc. (CH) 2008-06-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT BCOR, CBR3, SULT1E1 MEN1 1381/4885KMT2A 217/4885HTT 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback